Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cyclin-dependent kinase 4 | Starlite/ChEMBL | No references |
Homo sapiens | cyclin-dependent kinase 6 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma japonicum | ko:K02091 cyclin-dependent kinase 6, putative | Get druggable targets OG5_133618 | All targets in OG5_133618 |
Schistosoma mansoni | serine/threonine protein kinase | Get druggable targets OG5_133618 | All targets in OG5_133618 |
Echinococcus granulosus | cyclin dependent kinase 6 | Get druggable targets OG5_133618 | All targets in OG5_133618 |
Echinococcus multilocularis | cyclin dependent kinase 6 | Get druggable targets OG5_133618 | All targets in OG5_133618 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 6 | 326 aa | 314 aa | 31.2 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 4 | 303 aa | 312 aa | 29.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | serine/threonine protein kinase | 0.0203 | 1 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 6 | 0.0203 | 1 | 0.5 |
Loa Loa (eye worm) | leucine Rich Repeat family protein | 0.0195 | 0.9533 | 0.5 |
Onchocerca volvulus | 0.005 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 2.6 nM | BindingDB_Patents: In Vitro Assay. The Cdk4 and Cdk6 inhibitory activity of the compounds is measured with a kinase inhibition assay using recombinant Cdk4/CyclinD1 or Cdk6/CyclinD3 protein complexes. The protein substrate used in the assay is the retinoblastoma protein (Rb). The kinase reactions are carried out in a 96-well filter plate (MSDV N6B50, Millipore). Compounds are serially diluted in kinase buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM DTT, 1 mg/ml BSA) and added to the reaction mixture containing 2.5 ng/ml Cdk4/CyclinD1 or Cdk6/CyclinD3, 25 uM ATP, 10 uCi/ml [33P]-ATP, 0.1 ug/ml Rb in the kinase buffer. The mixture is incubated at room temperature for 1 hour and the proteins precipitated with an equal volume of 20% TCA. The plates are washed with 10% TCA according to the manufacturer's instruction and dried at room temperature. The amount of the phosphorylated Rb is determined with a TopCount (PerkinElmer). | ChEMBL. | No reference |
IC50 (binding) | = 4.9 nM | BindingDB_Patents: In Vitro Assay. The Cdk4 and Cdk6 inhibitory activity of the compounds is measured with a kinase inhibition assay using recombinant Cdk4/CyclinD1 or Cdk6/CyclinD3 protein complexes. The protein substrate used in the assay is the retinoblastoma protein (Rb). The kinase reactions are carried out in a 96-well filter plate (MSDV N6B50, Millipore). Compounds are serially diluted in kinase buffer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM DTT, 1 mg/ml BSA) and added to the reaction mixture containing 2.5 ng/ml Cdk4/CyclinD1 or Cdk6/CyclinD3, 25 µM ATP, 10 µCi/ml [33P]-ATP, 0.1 µg/ml Rb in the kinase buffer. The mixture is incubated at room temperature for 1 hour and the proteins precipitated with an equal volume of 20% TCA. The plates are washed with 10% TCA according to the manufacturer's instruction and dried at room temperature. The amount of the phosphorylated Rb is determined with a TopCount (PerkinElmer). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.